Kartal Kosuyolu High Speciality Training and Research Hospital
Istanbul, Eyalet/Yerleşke, 34800, Turkey (Türkiye)
NCT Number: NCT04773028
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Istanbul, Eyalet/Yerleşke, 34800, Turkey (Türkiye)
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery. Only 4% of patients with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension and acute pulmonary embolism or deep vein thrombosis is reported in the anamnesis of 75% of those with chronic thromboembolic disease. Therefore, the etiology of the disease is not clear. Altought many studies are done, especially the role of inflamation is emhasised underlie the disease.
Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension.
Matrix metalloprotinase enzymes are known to play a role in atherosclerosis. This research will investigate whether there is atherosclerosis together with inflamattion in the background of chronic thromboembolic hypertension.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
concentration of matrix metalloproteinase 2 and 9 enzymes
Time frame: 1 year
Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.
AHMET ZENGIN
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07704086
Aortic Diseases, Arterial Occlusive Diseases
Madrid, Spain
View Trial DetailsNCT03729544
Cardiovascular Diseases, Chronic Thromboembolic Pulmonary Hypertension
Boston, Massachusetts, United States
View Trial DetailsNCT05179356
Chronic Thromboembolic Pulmonary Hypertension, Hypertension, Pulmonary
Copenhagen, Denmark
View Trial DetailsNCT06384534
Cardiovascular Diseases, Chronic Thromboembolic Pulmonary Hypertension
Zurich, Canton of Zurich, Switzerland
View Trial Details